Iran National Science Foundation

National Science Foundation Issues Small Business Innovation Research (SBIR) Grant to The Wrightguard Innovations Corporation in Support of Novel Mouthguard Technology

Thursday, October 14, 2021 - 1:30pm

The grant, totaling $255,944, will support the company's Phase I research and development activities.

Key Points: 
  • The grant, totaling $255,944, will support the company's Phase I research and development activities.
  • TWGIC co-founder and UMSOD alumnus Dr. Wright said, "I am honored to receive this research grant on behalf of my team of co-developers.
  • We are confident and excited about this pivotal technology's potential to minimize injury risks to athletes at all levels."
  • The WrightGuard, the precursor to The WrightGuard Innovations Corporation (TWGIC) was established in 2011.

Grapheton, Inc. Appoints New CEO

Wednesday, October 13, 2021 - 9:27pm

Mr. Lingren joins Grapheton with a proven track record of leadership in growing technology startups from concept through market entry and high-volume manufacturing.

Key Points: 
  • Mr. Lingren joins Grapheton with a proven track record of leadership in growing technology startups from concept through market entry and high-volume manufacturing.
  • He was the founding CEO of Resonant Inc. in 2012 and led it through its initial public offering in 2014 before retiring in 2017.
  • Founded in 2019, Grapheton is an early-stage company commercializing brain probes and power sources made from glassy carbon and graphene.
  • He and his team have three patents around the use of glassy carbon for brain probes and supercapacitors, as well as interconnecting glassy carbon with graphene.

New SARS-CoV-2 Assay by CosmosID Eases Disruptions in Supply Chain for Patient Fecal Microbiota Transplantation

Tuesday, October 5, 2021 - 1:48pm

OpenBiome will now test its large inventory of FMT treatments manufactured after December, 2019, which had largely been previously ineligible for distribution per the FDA safety alerts.

Key Points: 
  • OpenBiome will now test its large inventory of FMT treatments manufactured after December, 2019, which had largely been previously ineligible for distribution per the FDA safety alerts.
  • The test allows OpenBiome to restore its supply chain of FMT treatments and once again make them widely available to patients.
  • "Screening our inventory using the stool-based assay developed by CosmosID will allow thousands of patients to get much-needed treatment for C. difficile infection.
  • The CosmosID platform uses proprietary sequence analysis algorithms to accurately profile all microorganisms in a metagenomic sample employing next-generation DNA sequencing.